Filed by e3 Filing, Computershare 1-800-973-3274 - Clementia Pharmaceuticals Inc. - Form 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of February 2019

Commission File Number: 333-219066

Clementia Pharmaceuticals Inc.
(Translation of registrant's name into English)

1000 de la Gauchetiere Street West, Suite 1200
Montreal, Quebec, CANADA , H3B 4W5
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.





The information contained in this Report (including the exhibits hereto) is hereby incorporated by reference into Clementia Pharmaceuticals Inc.’s Registration Statement on Form F-3 (File No. 333-227726).

On February 28, 2019, the Registrant provided a Notice of its Annual General Meeting which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Notice of Annual General Meeting dated February 28, 2019.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  Clementia Pharmaceuticals Inc.
  (Registrant)
 
Date: February 28, 2019  
  /s/ Steve Forte
  Steve Forte
  Chief Financial Officer

 



Exhibit 99.1
Exhibit 99.1


  1500 Robert-Bourassa Blvd.,
February 27, 2019 7th Floor
  Montreal QC, H3A 3S8
  www.computershare.com

To: All Canadian Securities Regulatory Authorities

Subject: Clementia Pharmaceuticals Inc.

Dear Sir/Madam:

We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:

Meeting Type : Special Meeting
Record Date for Notice of Meeting : March 08, 2019
Record Date for Voting (if applicable) : March 08, 2019
Beneficial Ownership Determination Date : March 08, 2019
Meeting Date : April 09, 2019
Meeting Location (if available) : Montreal, Qc
Issuer sending proxy related materials directly to NOBO: No
Issuer paying for delivery to OBO: Yes
 
Notice and Access (NAA) Requirements:  

NAA for Beneficial Holders

No

NAA for Registered Holders

No

 

Voting Security Details:    
 
Description CUSIP Number ISIN
COMMON SHARES 185575107 US1855751079

Sincerely,

Computershare
Agent for Clementia Pharmaceuticals Inc.